FOXO Technologies Inc. filings document the company’s healthcare operating subsidiaries, securities registrations, capital structure and governance actions. Current reports describe amendments to the certificate of incorporation, authorized-share increases, preferred-stock designations, Series E preferred stock transactions, shareholder written consents and Regulation FD updates tied to hospital and corporate operations.
The filing record also includes an S-1 registration statement, unregistered equity issuance disclosures, executive-officer transition reporting, an NT 10-K late-filing notice and formal disclosures on internal controls, financial reporting processes and SEC reporting obligations. These documents record FOXO’s public-company status, ownership and voting matters, financing arrangements, risk-related reporting and material corporate events.
FOXO Technologies Inc. entered into two Exchange Agreements with institutional investors to restructure its Series A Cumulative Convertible Redeemable Preferred Stock into senior unsecured non-convertible promissory notes. Investor 1 exchanged 2,467.98834 Series A shares with a stated value of $2,467,988.34 for an equal principal amount note, and Investor 2 exchanged 5,307.09694 Series A shares with a stated value of $5,307,096.94 for a matching principal amount note.
The exchanged preferred shares are cancelled, and the investors no longer hold instruments with conversion rights to FOXO equity. Each Senior Note is non-interest bearing, unsecured, and matures on the earlier of May 12, 2027 or the occurrence of an Event of Default, with an 18% per annum default interest rate. The company agrees not to incur indebtedness senior to these notes, repayment is to occur upon completion of a public offering or up-listing to a recognized stock exchange, and proceeds are earmarked for working capital purposes.
FOXO Technologies Inc. reports Q1 2026 results with net revenues of $5.17 million, up from $3.17 million a year earlier, mainly from its healthcare and life science services businesses. Despite higher revenue, FOXO recorded a net loss to common stockholders of $1.74 million.
The company ended March 31, 2026 with $65,896 in cash and a working capital deficit of $27.1 million, and it carries $8.61 million of current debt. Management discloses that these conditions and ongoing losses raise substantial doubt about FOXO’s ability to continue as a going concern absent additional financing and improved cash flow.
FOXO Technologies Inc. is amending its charter to increase its authorized capital to 25,020,000,000 shares. This will consist of 25,000,000,000 shares of Class A Common Stock and 20,000,000 shares of Preferred Stock, each with a par value of $0.0001 per share.
The Certificate of Amendment was authorized and approved by stockholders and adopted in accordance with Sections 212 and 242 of the Delaware General Corporation Law. It is scheduled to become effective upon filing with the Delaware Secretary of State on May 3, 2026.
FOXO Technologies Inc. files its annual report for the year ended December 31, 2025, describing a diversified business spanning rural hospitals, behavioral health, life science specimen sourcing, and epigenetic labs. The company has expanded via acquisitions of Myrtle Recovery Centers, Rennova Community Health and Vector BioSource, and now operates a 25-bed Critical Access Hospital and related behavioral health facilities in Tennessee.
FOXO reports substantial net losses, a working capital deficit and significant debt, and its auditors raise substantial doubt about its ability to continue as a going concern. The report details heavy reliance on equity financing, difficulty accessing a $5.0 million equity line, prior intangible asset impairments in the epigenetics division, and high regulatory exposure across healthcare, life science services and lab activities. Control of voting power by a preferred stockholder and challenges completing a further reverse stock split weigh on capital structure flexibility and liquidity.
The Board and the holder controlling a majority of votes approved an amendment to increase authorized Class A Common Stock from 10,000,000,000 to 25,000,000,000 shares. The approval was by unanimous board consent on March 20, 2026 and by written shareholder consent on March 27, 2026.
The Authorized Increase becomes effective when the Certificate of Amendment is filed with the Delaware Secretary of State after the 20-day mailing period required by Rule 14c-2(b). As of the Record Date the Company had 3,732,660,939 shares of Common Stock outstanding.
FOXO Technologies Inc. states that its Board and a majority holder approved an amendment to increase authorized Class A Common Stock from 10,000,000,000 to 25,000,000,000 shares. The Board adopted the proposal on March 20, 2026 and the majority holder consented on March 27, 2026. The amendment becomes effective upon filing the Certificate of Amendment with the Delaware Secretary of State after the required 20‑day mailing period. As of the Record Date the company reported 3,732,660,939 shares of Common Stock outstanding and aggregate voting power of 196,232,517,288 votes. The Information Statement notes potential uses of the additional shares for conversions, financings, equity incentives, strategic transactions, and other corporate purposes.
FOXO Technologies Inc. reported a leadership change in its finance function. On March 18, 2026, Chief Financial Officer and Principal Financial and Accounting Officer Sylwia Nowak Hauman resigned, citing concerns about the company’s internal control environment, financial reporting processes, and staffing of the finance team. The company states it disagrees with these characterizations and believes its controls, reporting processes, and staffing are adequate and significantly improved under current management, and it emphasizes its commitment to timely SEC reporting, including the upcoming 10-K. On March 24, 2026, FOXO appointed Celene Laurene Rattray Grant, a CPA with over 15 years of experience and prior consulting roles with the company, as the new Chief Financial Officer. Ms. Grant will receive a base salary of $200,000 and be eligible for a discretionary annual bonus of up to $25,000.
FOXO Technologies Inc. is registering up to 1,000,000,000 shares of Class A Common Stock for potential resale by ClearThink Capital Partners under an equity purchase agreement. These shares may be issued to ClearThink at a discount to market and then resold over time.
FOXO will not receive any proceeds from ClearThink’s resales, though it may raise up to $5,000,000 by issuing stock to ClearThink through June 30, 2026 under the agreement. Class A Common Stock outstanding was 3,062,660,939 shares as of February 5, 2026, and could rise to 4,062,660,939 shares if all registered shares are issued.
The company discloses limited cash, substantial historical losses, going concern language from its auditor, prior reverse stock splits, delisting from NYSE American, thin OTC trading, and “penny stock” status. Risk factors emphasize significant potential dilution, pressure on the share price, and heavy voting control by preferred stock and RHI.